

Selected Proceedings From the 2023 European Musculo-Skeletal Oncology Society Meeting
Guest Editor: Pietro Ruggieri MD, PhD

Editorial Comment: 35th Annual Meeting of the European Musculo-Skeletal Oncology Society (EMSOS)

Pietro Ruggieri MD, PhD¹ 

Received: 29 March 2024 / Accepted: 10 April 2024 / Published online: 7 May 2024
Copyright © 2024 by the Association of Bone and Joint Surgeons

It is my pleasure to introduce the brand new collaboration between the European Musculo-Skeletal Society (EMSOS) and *Clinical Orthopaedics and Related Research*®. The opportunity to publish selected proceedings from EMSOS meetings every year has made me, the other Board members, and all EMSOS members very happy, as we are proud to have *CORR*® as the official journal of our society.

Our 2023 meeting took place in Brussels, Belgium on May 10–12, 2023. It had an excellent program and remarkable participation, with over 600 attendants registered. The organizing committee was locally chaired by Ramses Forsyth, a pathologist in Brussels and Past President of EMSOS; Gwen Sys from the Cancer Research Institute in Ghent, Belgium; and myself, the current President of EMSOS.

The first day of the meeting was a training day designed for young members, residents, and researchers. It also included four sessions for PhDs and young investigators, each on basic



Pietro Ruggieri MD, PhD

The author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members.

All ICMJE Conflict of Interest Forms for authors and *Clinical Orthopaedics and Related Research*® editors and board members are on file with the publication and can be viewed on request. The opinions expressed are those of the writers, and do not reflect the opinion or policy of *CORR*® or The Association of Bone and Joint Surgeons®.

¹Chairman, Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Veneto, Italy

P. Ruggieri ✉, University of Padova, Department of Orthopedics, Via Giustiniani, 2, Padova, Veneto 35128, Italy, Email: pietro.ruggieri@unipd.it

and translation research, surgical treatment options, diagnostics [13], and nonsurgical treatment options [12]. A research session on nursing and psychosocial research was also held for our nurses and allied professionals, whose participation is constantly encouraged. The talk of the day—our Brussels Lecture—was delivered by Gwen Sys with the title: “Inspiring Times: Playing the Infinite Game in Sarcoma Care and Research.” Appreciated by the audience, it underlined the close correlation between research and clinical care in the treatment of sarcoma [1, 15], thus emphasizing the importance of translational research.

On the second day, the opening ceremony included welcome addresses from Ramses Forsyth, Gwen Sys, and myself. We also enjoyed receiving a video message from Seth Leopold MD, Editor-in-Chief of *CORR*®, introducing EMSOS members to their official journal and informing all the society members of the advantages gained by such a collaboration.

Then, Fabrice Fiorenza (France) and Olivier De Wever (Belgium) chaired a session on basic and translation science. Other sessions on digital innovations and telediagnosics highlighted the relevance of newer technologies and AI in musculoskeletal oncology practice and research. The EMSOS lecture of the day, entitled “Translational Sarcoma Research: Reflections on Collaboration,” was given by Judith Bovée (The Netherlands), and I provided the traditional Presidential Lecture, this year entitled “Multidisciplinarity: A True Modern Approach to Musculoskeletal Oncology and a Pillar for EMSOS.” The many posters on display sparked a number of engaging debates.

The third day hosted sessions on pelvic tumor treatments, pediatric reconstructions, treatment severity, and shared decision-making in bone reconstructions [2, 3, 11]. A brilliant Campanacci Lecture, entitled “Pitfalls to Avoid in Bone Reconstruction of Children. Critical Considerations After 40 Years of Experience,” was presented by Marco Manfrini. This gave us the opportunity to celebrate Dr. Manfrini’s retirement and listen to the wisdom gained over his long career and professional experience. A final session, entitled “How Do we go Further to Achieve Structural Collaboration?” is of utmost importance for EMSOS, in order to plan for future needs and achievements in the field of musculoskeletal oncology [8].

Seven papers have been chosen and published here in *CORR*® as selected proceedings from the 2023 EMSOS meeting. Three of them deal with techniques of reconstruction for bone tumors in the proximal humerus, pelvis, and tibia [4-6]; one focuses on prognosis of mistreated soft tissue tumors [7]; while the remaining papers are about molecular biology and/or pathology in cartilaginous tumors or soft tissue sarcomas [9, 10, 14].

The way the 35th EMSOS Meeting was organized, along with the papers chosen for publication in *CORR*®, demonstrates the spirit of the society: emphasizing the value of multidisciplinarity, the need for translational research, and active participation by EMSOS members. EMSOS is a collaborative society, and our members include not just orthopaedic surgeons, but also medical oncologists, pathologists, radiation therapists, nurses, psychologists, engineers, and people from other disciplines, all of whom share a passion for musculoskeletal oncology research and high-quality care for patients with bone and soft tissue tumors.

EMSOS 2024 will take place in Poland, and papers from that meeting will be published in next year’s selected proceedings in *CORR*®.

References

1. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, Ruggieri P. Clinical outcome of central conventional chondrosarcoma. *J Surg Oncol*. 2012;106:929-937.
2. Aponte-Tinao LA, Ayerza MA, Albergo JI, Farfalli GL. Do massive allograft reconstructions for tumors of the femur and tibia survive 10 or more years after implantation? *Clin Orthop Relat Res*. 2020;478:517-524.
3. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. *N Engl J Med*. 1999;341:342-352.
4. Campanacci DA, Scanferla R, Marsico M, et al. Intercalary resection of the tibia for primary bone tumors: are vascularized fibula autografts with or without allografts a durable reconstruction? *Clin Orthop Relat Res*. 2024;482:960-975.
5. Errani C, Aiba H, Atherley A, et al. What is the revision-free survival of resurfaced allograft-prosthesis composites for proximal humerus reconstruction in children with bone tumors? *Clin Orthop Relat Res*. 2024;482:979-990.
6. Fragnaud H, Biscaccianti V, Hascoët JY, et al. How does customized cutting guide design affect accuracy and ergonomics in pelvic tumor resection? A study in cadavers. *Clin Orthop Relat Res*. 2024;482:994-1002.
7. Gómez-Álvarez J, Lamo-Espinosa JM, San-Julian M. Do patients treated with an unplanned resection for small superficial soft tissue sarcomas have worse long-term survival than those initially treated with an oncologic resection? *Clin Orthop Relat Res*. 2024;482:1017-1024.
8. Grimer RJ, Aydin BK, Wafa H, et al. Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. *Bone Joint J*. 2016;98:857-864.
9. Kim H, Joo MW, Yoon J, et al. Can DNA methylation profiling classify histologic subtypes and grades in soft tissue sarcoma? *Clin Orthop Relat Res*. 2024;482:1028-1037.
10. Laitinen MK, Parry MC, Morris GV, Kurisunkal V, Stevenson JD, Jeys LM. Can the cartilaginous thickness determine the risk of malignancy in pelvic cartilaginous tumors, and how accurate is the pre-operative biopsy of these tumors? *Clin Orthop Relat Res*. 2024;482:1006-1016.
11. Ruggieri P. *CORR insights*®: proximal femur replacements for an oncologic indication offer a durable endoprosthetic reconstruction option: a 40-year experience. *Clin Orthop Relat Res*. 2023;481:2244-2246.
12. Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: an overview and update. *Lancet Oncol*. 2000;1:75-85.
13. Smolle MA, Andreou D, Tunn P-U, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. *EFORT Open Rev*. 2017;2:421-431.
14. Trovarelli G, Sbaraglia M, Angelini A, et al. Are IDH1 R132 mutations associated with poor prognosis in patients with chondrosarcoma of the bone? *Clin Orthop Relat Res*. 2024;482:947-956.
15. Yuan J, Li X, Yu S. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. *Cancer Control*. 2021;28:10732748211038424.